The molecular mechanisms underlying the development and evolution of myelodysplastic syndrome (MDS) are largely unknown. The increasing number of blast cells in the bone marrow correlate with poor prognosis and risk of developing acute leukemia. Such progression is frequently associated with increasing chromosomal abnormalities and genetic mutations. A cohort of 75 MDS patients were investigated for RAS, FMS and p53 mutations, and these molecular findings were related to cytogenetics, clinical status, transformation to acute leukemia, prognostic scores and survival. A mutation incidence of 57% (43/75) was found, with 48% (36/75) RAS mutations, 12% (9/75) FMS mutations and 8% (4/50) p53 mutations. The mutation status for RAS and FMS was related to MDS subgroup, increasing with poor-risk disease. The highest incidence was in the chronic myelomonocytic leukemia (CMML) subgroup. The most frequent RAS mutations were of codon 12 and a predominance of FMS codon 969 mutations was observed. A statistically significant increased frequency of transformation to AML was observed in MDS patients harboring RAS or FMS mutations (P Ͻ 0.02). Patients with oncogene mutations had a significantly poorer survival compared with those without mutations at 2 years and at the end of the period of follow-up (P Ͻ 0.02). Multivariate analysis including mutation, age, gender, diagnosis (FAB), cytogenetics and International score shows that the International score and mutation and age is the best predictive model of a poor outcome, (P Ͻ0.0001). When the analysis was undertaken without the International score, mutation and gender was the best predictor of poor survival (P = 0.005). This study shows that oncogene mutation, indicative of genetic instability, is associated with disease progression and poor survival in MDS.
Introduction
Myelodysplastic syndromes (MDS) represent a 'preleukemic' state in which there is a failure of the hematopoietic progenitors to differentiate normally. MDS is characterized by hypercellular bone marrow with peripheral blood cytopenias and biochemical evidence of ineffective hemopoiesis. 1 This suggests significant intramedullary death and some have suggested that this may be due to a high degree of apoptosis. 2 MDS is considered to be preleukemic as approximately onethird of all patients eventually progress to an acute leukemic state often acute myeloid leukemia (AML). However, many patients do not survive the cytopenic effects of MDS and thus it is difficult to determine the true leukemic potential of the disease.
In 1982 the French-American-British (FAB) co-operative group provided a classification of MDS on the morphological appearance of the blood and bone marrow cells. 3, 4 Increasing numbers of blast cells in the bone marrow correlates with poor prognosis and increased relative risk of disease progression to AML. Several scoring systems, namely the Bournemouth, Sanz and Lille among others, have included additional parameters such as age, platelet count, white blood cell count and hemoglobin level as well as cytogenetics, which have also been predictive of prognosis. [5] [6] [7] Recently, an International scoring system has been devised to incorporate the important prognostic parameters, which was agreed by authors of the other scoring systems. 8 The different FAB subgroups are thought to represent different stages of preleukemic progression and therefore MDS is a good model for the study of leukemic evolution.
The incidence of chromosomal abnormalities in MDS patients tends to increase with poor risk and more abnormalities being found in the more aggressive groups of refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-t) and chronic myelomonocytic leukemia (CMML) than in the more benign refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS). 9, 10 Multiple chromosomal changes are associated with leukemic change and a more rapid disease progression, while single abnormalities, except monosomy 7, implicate a similar prognosis to that of normal karyotypes when found in MDS patient samples. However, trisomy 8 is associated with a poor prognosis. It is becoming increasingly evident that chromosomal and genetic abnormalities are indicative of genomic instability and cancer progression in solid tumors and leukemia. 7, 11, 12 We present here a study of multiple molecular markers in a cohort of MDS patients and the investigation of their correlation with clinical status and progression to acute leukemia. The presence of RAS, FMS and p53 mutations in peripheral blood and bone marrow samples from 75 MDS patients of all FAB subtypes was investigated and related to transformation to AML, karyotype, survival and to the International score. This is a detailed study of multiple molecular, cytogenetic and clinical markers with statistical investigations of their relevance to disease progression and prognosis.
Materials and methods

Patient samples
Bone marrow (BM) and/or peripheral blood (PB) was collected after informed consent. These studies were approved by the South Glamorgan Ethical committee. The patients investigated were diagnosed as belonging to the following FAB subtypes: RARS n = 16; RA n = 17; RAEB/t n = 10; CMML n = 32. There were 41 males and 34 females in the study. The age range was 19-89 years (mean 68 years). The CMML patients were selected on the basis of their high white blood cell count and were considered to be of high risk. 5 High molecular weight DNA was extracted by a modified proteinase K phenol method. 13 
Cytogenetic analysis
Cytogenetic investigations were performed by GTG banding and classified according to the International System for Human Genetic Nomenclature (ISCN).
14 Karyotypes were obtained from 58 of the 75 patients.
Polymerase chain reaction (PCR) and oligonucleotide hybridization (ONH) for RAS mutations ONH was performed to identify point mutations at specific codon sites. Sequences of around 100 bp were amplified using primers flanking codons 12/13 and 61 of H, K and NRAS as described previously. [15] [16] [17] Where sufficient DNA was available, independent confirmation of the results obtained by ONH was obtained using NIH3T3 transformation assays as described. 15, 18 Foci were scored 3-4 weeks after transfection, picked, expanded and their DNA extracted for further analysis by Southern blot and SSCP. Alternately, tumorigenicity assays 15, 19 were used. Tumors that appeared with latency periods of 3-6 weeks were analyzed further by Southern blot 15 and SSCP. Single-stranded conformational polymorphism (SSCP) analyses 20 followed by cloning and sequencing was performed in two of the patients as described previously. 21 A further 25 patients were analyzed from the 50 originally published. 15 
PCR and ONH for FMS mutations
Amplifications of the sequences of interest were performed by a modified version of the PCR reaction 17 using primers flanking codons 301 and 969 of the FMS gene and published previously. 21, 22 Confirmation of FMS mutations by cloning and sequencing from patient material has been published elsewhere. 21, 23 PCR for p53 exons 5-8 PCR reactions were performed using a modified version of the standard method 17 using the 'Touchdown' programs of thermocycling. 24 Exons 5-8 of the p53 gene were amplified and PCR products were analyzed for mutations by SSCP as described previously. 11 Fifty of the 75 patients in this cohort were analyzed. Aberrantly migrating SSCP bands were eluted from the gel, cloned using the pT7 blue vector (Novagen, Madison, WI, USA), purified and sequenced using Sequenase version 2.0 (Cambridge Bioscience, Cambridge, UK).
Survival analyses
A univariate analysis of survival was estimated by the KaplanMeier method from the date of sampling. Survivals of mutants (n = 42) and non-mutants (n = 33) were compared first by the Mantel-Haenszel (or log rank) method for the maximum period of observation (10 years) and for the first 2 years. Multivariate analyses of survivals were also analyzed in a series of Cox proportional hazards models with gender (M,F), age (р69, у70), diagnosis as defined by FAB (RARS, RA, RAEB and CMML), mutation (mutant, non-mutant), cytogenetics (normal, any variant) and International scores 8 as potential explanatory variables. P values of Ͻ0.05 were considered as statistically significant.
Results
Cytogenetics
Cytogenetic investigations indicated that 58 of the 75 MDS patient samples had metaphase spreads suitable for analyses. Cytogenetic abnormalities were detected in two of 15 (13%) RARS, five of 12 (42%) RA, in four of eight (50%) RAEB/t and in five of 23 (22%) CMML patients.
RAS mutations
Of the patients analyzed by ONH, SSCP analyses and sequencing we found RAS mutations and activated RAS by NIH3T3 transformation and Southern blot analyses in 36 of 75 (48%) patient samples (Table 1 , representative SSCP gel is shown on Figure 1 ). Two CMML patients were confirmed by sequencing and found to have aspartic acid substitutions (data not shown). This includes data on 50 patients published previously 15 and 25 additional patients. The majority of the mutations were of NRAS (n = 21), then KRAS (n = 11). Most of the mutations were of codon 12 (n = 25). Of statistical significance was the increased frequency of RAS mutations in the CMML patient group with 21 of 32 (66%) patients harboring RAS abnormalities compared to the other subgroups investigated ( 2 = 8.4, df = 1, P Ͻ 0.01).
Of 36 patients with RAS mutations cytogenetics were known for 28. In these patients with RAS mutations one of four (25%) of RARS, two of five (40%, one not known) of RA, two of four (50%, one not known) of RAEB and four of 15 (21%, seven not known) of CMML also had cytogenetic abnormalities. These rates of cytogenetic abnormalities were similar to those rates observed in patients irrespective of their RAS status, indicating that in each patient group no statistically significant increase in the rate of cytogenetic abnormalities was associated with the presence of RAS mutations. A total of 46 patients were tested using the NIH 3T3 transformation assay and 28 (61%) had transforming activity.
FMS mutations
Of the 75 MDS patients investigated by ONH, for FMS mutations nine (12%) were found to have mutations at either codons 301 (n = 1) or 969 (n = 8) ( Table 1) . Most of these results have been published previously. 22 Only one of the patients with FMS abnormalities was found to have an abnormal karyotype, and one patient had no suitable metaphases for analyses. This frequency of abnormalities in the mutated FMS group of MDS patients indicates that FMS mutations were not asssociated with abnormal karyotypes.
p53 mutations
A total of four of the 50 (8%) MDS patients investigated for p53 mutations (25 not done) were found to have mutations (Table 1, Figure 2 for representative sequence). Two of the 11 (18%) patients investigated in the RARS subgroup exhibited exon 7 codon 248 substitutions (CGG→CAG, Arg→Gln) (Figure 2) . One of the 11 (9%) patients in the subgroup RA had an exon 8 codon 286 substitution (GAA→CAA, Glu→Gln) (data not shown). One of the 10 (10%) RAEB patient samples investi- gated harbored an exon 5 codon 174 deletion (AGG→AG) (data not shown). This mutation changes the reading frame of subsequent amino acids and creates a stop at codon 221 in exon 6 in the DNA binding domain. Three of four patients with p53 mutations had abnormal karyotypes. The fourth patient had no suitable metaphases for analyses (Table 2 ). Although the numbers of patients with p53 mutations was too small for statistical analyses, the incidence of karyotypic abnormalities was perhaps higher than expected from the frequency of chromosomal abnormalities in the sample group.
Multiple genetic mutations
Some patients had multiple mutations (Table 1 ). In the RA group of patients one of the six patients with a RAS mutation also had a FMS or a p53 mutation. In the RARS group one of the four patients who had a RAS mutation also had a p53 mutation. In the RAEB group one patient had a RAS and a FMS mutation. In the CMML group three of the 21 patients (14%) with RAS mutations also had FMS mutations.
Transformation to acute leukemia
Of the 20 of 75 (27%) patients, who transformed to AML, 16 had RAS and/or FMS mutations, which indicates an increased frequency of transformation in patients harboring a RAS and/or FMS mutation. Six patients were investigated at both the MDS and AML stages of the disease. One patient acquired a FMS mutation upon progression. Another patient had evidence of mutant RAS and FMS, respectively, in both MDS and AML stages. Two CMML patients had detectable FMS and RAS mutations, which were lost upon disease progression. One of these patients also had different RAS mutations associated with the different stages of the disease. However, none of the four patients with a p53 mutation transformed to AML. Of the 36 patients with RAS mutations, 14 transformed to AML (41%) and two of four with FMS mutations alone transformed to AML, significantly more than those with p53 alone (0/2) or no mutation (4/33) ( 2 = 6.4, df = 1, P Ͻ 0.02).
Survival
The result of the univariate analysis is shown in Table 3 . Survival analysis by mutation status showed poorer survival among the 42 patients with mutations than among the 33 patients without detectable mutations (two were death registrations and two have zero follow-up) (Figure 3 
) (Mantel
Figure 3
Survival of MDS patients and oncogene mutations.
Haenszel log rank 2 = 5.45, P Ͻ 0.02). This was significant for the first 24 months of observation and after 10 years follow-up. The International score and the FAB classification were both significant ( Table 3) .
As karyotypes have been shown by several studies to have prognostic significance, statistical analysis was conducted selecting the International score as the most recent scoring system which includes cytogenetics as one of the parameters taken into account. This scoring system differentiates between the different chromosomal abnormalities according to prognosis. 8 The results of a Cox proportional hazard modeling including age (n = 74), gender (n = 75), diagnosis (FAB, n = 75), mutation (n = 75) and International (n = 54) score shows that International (P = 0.0002) and mutation (P = 0.02) and age (0.03) were best for predicting outcome. The overall significance for this model is P Ͻ 0.0001.
When the analysis was done with only RAS mutations and FMS and p53 mutants were considered normal, its prediction improved (logrank 2 = 5.80, P Ͻ 0.02) and in the first round of Cox ( 2 = 8.81, P = 0.003) but was no better in subsequent rounds than the analysis with all three genes. Interestingly, when the International score was omitted from the analysis, the optimum model for predicting poor outcome was mutations + gender in Cox round 2 ( 2 = 11.407, df = 2, P = 0.005). In the third round, the addition of age did not improve the prediction significantly (mutations + gender + age ( 2 = 14.948, df = 3, P Ͻ 0.005)).
Discussion
The RAS proto-oncogene family consists of three family members, H, K and N, each encoding a 21 kDa plasma membrane protein (p21), which binds to GTP. P21RAS has an important role in the signal transduction pathway and can be activated by point mutations at codons 12, 13 and 61, which correspond to the GTP-binding sites. 25 We found RAS mutations at a frequency of 48% in all MDS subtypes and frequencies of mutation appear to increase with risk as found by other investigators. 26 Others have found RAS mutations at frequencies of between 3 and 40%. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] The heterogeneity of incidence of RAS mutations observed may reflect differences in patient selection and methods of detecting mutations. As medical schools are referral centers the cases seen may be selected and this is certainly true of our CMML cases, which were mostly in the high-risk group. 5 The biological NIH3T3 transformation assay confirmed the RAS mutations detected by ONH.
In hematopoietic cells NRAS and KRAS p21 proteins are expressed at higher levels than HRAS p21. 37 We have previously observed deregulation of p21RAS in MDS. 38 As with our study, higher frequency of NRAS mutations and a lower frequency of KRAS mutations has been reported in hematological malignancies, 26 suggesting a specific role of these genes in the growth control of hematopoietic cells. We found that patients harboring RAS mutations exhibited a significant decrease in survival compared to those without mutations and an increased transformation to AML. This has been confirmed in a study of NRAS codon 12 mutations in over 200 MDS cases, where a decrease in survival was observed in patients harboring mutations. 34 In our study, the presence of a RAS mutation was not associated with gross cytogenetic abnormalities.
The FMS gene encodes a functional receptor for the growth factor colony-stimulating factor (CSF-1 or M-CSF).
39 M-CSF is required for normal cell proliferation and survival of monocytes. FMS mutations have been found in 12 and 20% of MDS patients at codons 301 and 969 by us 22 and others. 40 Mutations at codon 301 mimic the ligand-induced conformational change produced by CSF-1 binding and causes altered protein tyrosine kinase activity and transforming ability in NIH3T3 cells. 41, 42 However, this is not the case in FDCP-1 (hematopoietic) cells in which the 301 FMS mutation is not transforming whereas the 969 mutation renders the cells growth factor (IL-3) independent, 43, 44 tumorigenic in nude mice and the mutant receptor is not saturateable. 45 It is not surprising, therefore, that the majority of FMS mutations found in MDS patient samples to date have been at codon 969, 22, 40 occurring in all subgroups of MDS with the highest frequency in CMML. The presence of FMS mutations in patients was not found to be associated with cytogenetic abnormalities. The presence of FMS mutations was found in this study to be associated with an increased transformation to AML and a poor survival.
The p53 tumor suppressor gene is located at chromosome 17p13.1 and has been found to be the most frequently mutated gene in many forms of solid tumors. 46 However, this has not been found to be the case in many de novo hematological neoplasms 47 and it would appear that unlike RAS, p53 gene mutations are not frequent in MDS. [48] [49] [50] [51] [52] [53] [54] Although chromosome 17 abnormalities are associated with MDS disease progression, 55 we did not find any chromosome 17 abnormalities in the 58 MDS patients cytogenetically analyzed in this study. Previous groups have found p53 mutations predominantly in the poor-risk FAB subtypes of RAEB, RAEB-t and CMML, [48] [49] [50] [51] [52] [53] [54] and associated with chromosome 17p cytogenetic abnormalities. 49, 51, 54 However, three of the patients with p53 mutations in our study had karyotypic abnormalities and therefore belonged to a poor prognostic group, 7 while the fourth was not informative. Interestingly, two of the four patients with p53 mutations also had RAS mutations. Mutations of the p53 gene have been described with a slightly higher frequency in AML patients. 56, 57 None of the 20 patients who transformed to AML in our study harbored a p53 mutation and like others, we found that p53 mutations do not appear to play a significant role in the transformation of MDS to AML. Furthermore, we did not observe stabilization of p53 protein in a further 41 MDS cases, again confirming the lack of p53 involvement in the majority of MDS. 58 The appearance and disappearance of RAS and FMS lesions during progression of the disease suggest that these mutations were not initiating events in MDS and are somatically acquired. However, we have shown that when mutant NRAS is introduced into human CD34
+ cells, biological abnormalities of the erythroid lineage characteristic of MDS such as reduced erythroid colony growth, increased apoptosis, retardation of differentiation were observed. 59 An univariate analysis shows that the International score was significant at predicting poor outcome, however, mutation also was an independent predictor of survival. Patients with an oncogene mutation have a poorer survival. In the multivariate analysis the International score and mutation and age were the best predictive model for survival. Interestingly, not only was RAS mutation the most abundant abnormality observed of the three genes investigated, but alone, it was more significant than when all the genes were analyzed collectively in both the univariate and the first round of the multivariate analyses. When the analysis was undertaken without including the International score, but including FAB, mutations and gender was found to be significant. Gender has not been found to have a prognostic significance in other studies on MDS 60 and our finding may well be due to the general observation that females tend to live longer than males. As gender alone was not predictive of a poor outcome and only emerged together with oncogene mutation, other unmeasured factors may account for this association. For example, the cohort was an elderly population and in a generation where males experienced higher occupational exposure than females. 61 This study has elucidated the interaction between several factors and prognosis for MDS. We have performed a multivariate study on MDS patients who were examined clinically, karyotypically and genetically to determine if these parameters provided statistically significant indications of prognosis. We found that patients harboring oncogene mutations had a significantly poorer outcome compared with those without mutations.
